Engineered Human Liver Tissue Grows in Mice

Tissue “seeds” made up of three cell types and patterned onto a scaffold develop into complex structures with some organ function, researchers show.

Written byAnna Azvolinsky
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Microscopic image of a liver tissue seed grown in a mouse (hepatocytes in green, blood vessels in magenta)CHELSEA FORTIN, KELLY STEVENS, UNIVERSITY OF WASHINGTON, SEATTLE, SANGEETA BHATIA, MIT, BOSTONEngineering human livers is a lofty goal. Human liver cells, hepatocytes, are particularly difficult to grow in the laboratory as they lose liver functions quickly in a dish. Now, in a study published today (July 19) in Science Translational Medicine, researchers show that a “seed” of human hepatocytes and supporting cells assembled and patterned within a scaffold can grow out to 50 times its original size when implanted into mice.

These engineered livers, which begin to resemble the natural structure of the organ, offer an approach to study organ development and as a potential strategy for organ engineering.

“What blew my mind is that when we implant these tissues into a mouse with liver injury, the tissue seeds just blossom,” says study author Kelly Stevens, who conducted the experiments as a postdoc in Sangeeta Bhatia’s lab at MIT and now runs her own bioengineering lab at the University of Washington. “Nature takes over and self-assembles a structure that looks like a human liver and has many liver-associated functions.”

“This is a very exciting approach and another demonstration that we can build a basic liver unit using three basic cell types,” says Tammy Chang, an assistant ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies